What Asian Alliance Radiation & Oncology does

Asian Alliance Radiation & Oncology (AARO) is a Singapore-based private radiation oncology practice established in 2015 as Singapore's first independent radiotherapy practice, founded by radiation oncologists recruited from the National Cancer Centre Singapore. AARO operates a comprehensive cancer care platform anchored by the Centre for Stereotactic Radiosurgery (CSR) — launched December 2021 as the region's first dedicated frameless SRS/SBRT facility — and supports nine distinct cancer specialty segments including brain/spine, breast, prostate, liver, lung, gastrointestinal, gynaecological, head and neck, and advanced/metastatic cancers. The clinical offering spans radiation therapy modalities (SRS/SBRT, IMRT, IGRT, 3D-CRT, brachytherapy, VMAT, proton therapy), supporting treatments (chemotherapy, immunotherapy, hormone therapy, targeted therapy), theranostics (Yttrium-90 SIRT, Radium-223, Lutetium-177 PSMA, Lutetium-177 Octreotate), and minimally-invasive procedures (cryoablation, radiofrequency ablation).

The business model is fee-for-service specialist medical practice operating across seven locations — a flagship dedicated radiosurgery centre at Crawfurd Hospital plus satellite clinics at six premium Singapore private hospitals (Farrer Park, Gleneagles, Mount Alvernia, Mount Elizabeth, Novena), with international expansion into Penang, Malaysia via a June 2026 strategic alliance with Mount Miriam Cancer Hospital. Go-to-market combines direct physician-to-patient consultation, GP/specialist referral networks, and public cancer-awareness partnerships with the Singapore Cancer Society, 365 Cancer Prevention Society, and media outlets (CNA, CNA938). AARO accepts Medisave, Medishield Life, Integrated Shield Plans, and all major insurance panels, with PDPA-compliant patient data handling. Revenue mechanics rely on specialist consultations, treatment procedures, imaging services, and theranostics billed to patients and insurance providers — pricing is not publicly disclosed.

The team includes seven named specialist physicians led by Medical Director Dr. David Tan Boon Harn and Medical Director of CSR Dr. Jonathan Teh Yi Hui, alongside Director Dr. Daniel Tan Yat Harn (ISRS Board member), Women's & Children's Program Director Dr. Michelle Tseng Shu Fen, and Senior Nuclear Medicine Physician Dr. Andrew Tan Eik Hock. Differentiation rests on first-mover positioning (first independent practice, first SRS/SBRT programs for spine/prostate/liver in SE Asia), clinical outcomes (97% prostate cancer control at 5 years per published data), advanced imaging-guided platforms (Elekta Monaco 6.1.4, MRI-fusion), and specialty adjacencies such as SpaceOAR Hydrogel and Deep Inspiration Breath Hold. The practice is privately held with no disclosed external investors or parent entity.

Name

Asian Alliance Radiation & Oncology

Legal name

Asian Alliance Radiation & Oncology

Website

https://aaro.sg

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

AARO is a Singapore-based independent radiation oncology practice founded in 2015, operating seven clinical sites including the region's first dedicated SRS/SBRT facility, delivering advanced radiotherapy, theranostics, and supportive cancer care across nine specialty segments.

Ownership category

akta.pro rank

Product category

Radiation Oncology Services

NAICS

Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Medical Oncology (HLAKAFAB), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

• Radiation oncology
• Stereotactic radiosurgery
• Cancer treatment services
• Nuclear theranostics therapy
• Brachytherapy treatment

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Radiation Oncology Consultations and Treatment: Direct medical services including consultations, radiation therapy treatments (SRS/SBRT, IMRT, IGRT), brachytherapy, and other oncology procedures billed to patients or insurance providers.
2. Diagnostic and Imaging Services: MRI-guided planning, CT simulation, and other imaging services associated with radiation treatment planning.
3. Theranostics Services: Nuclear medicine therapies including Lutetium-177 PSMA, Radium-223, and Yttrium-90 SIRT for targeted cancer treatment.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Asian Alliance Radiation & Oncology (AARO) provides specialist radiation oncology consultations and treatments to cancer patients across multiple Singapore hospital locations, anchored by the Centre for Stereotactic Radiosurgery (CSR) - the region's first dedicated frameless SRS/SBRT facility. Core offerings include Stereotactic Radiosurgery (SRS/SBRT), Brachytherapy, IGRT, IMRT, 3D Conformal Radiation Therapy, Proton Therapy, Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Cryoablation, Radiofrequency Ablation, and a Theranostics clinic delivering Yttrium-90 SIRT, Radium-223, and Lutetium-177 therapies, supported by specialized cancer clinics and the RECOVER@AARO side effects program.

Product overview

Asian Alliance Radiation & Oncology (AARO) is a Singapore-based oncology practice offering a comprehensive cancer care platform centered on advanced radiation therapies. The flagship offering is the Centre for Stereotactic Radiosurgery (CSR) — the region's first dedicated frameless SRS/SBRT facility. The portfolio encompasses radiation therapy technologies (SRS/SBRT, IMRT, IGRT, 3D-CRT, Brachytherapy), cancer treatments (Immunotherapy, Chemotherapy, Hormone Therapy, Targeted Therapy, Proton Therapy, Cryoablation, Radiofrequency Ablation), and a network of Signature Cancer Clinics including Prostate SBRT Clinic, Liver Metastases Clinic, Lung SBRT Clinic, Theranostics Clinic, and RECOVER@AARO for radiation side effects. The Theranostics Clinic provides nuclear medicine therapies including Yttrium-90 SIRT, Radium-223, Lu-177 PSMA, and Lu-177 Octreotate. Together, these offerings provide one-stop personalized cancer care from diagnosis through treatment to survivorship.

Differentiator

Problem solved

Functional benefit

Products and services

• Centre for Stereotactic Radiosurgery (CSR) The region's first dedicated frameless Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) facility, offering advanced technologies and multi-disciplinary expertise under one roof for cancer patients requiring precision radiotherapy.
• Stereotactic Radiosurgery (SRS/SBRT) Highly targeted ablative radiation treatment that delivers high doses of radiation to a target within the body in one to five sessions using a specialised coordinate system allowing multiple sharply focused X-ray beams to hit small targets; suitable for brain, spine, prostate, liver, and lung tumors.
• Brachytherapy (Internal Radiation Therapy) Internal radiation therapy in which radioactive sources are placed inside or near the tumor, including image-guided brachytherapy for gynaecological cancers (cervix, uterus).
• Advanced External Beam Radiation Therapy (IMRT, IGRT, 3D-CRT, VMAT) Consolidated external beam radiation therapy modalities including Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), 3D Conformal Radiation Therapy, and Volumetric Arc Therapy (VMAT) for precise tumor targeting with sparing of surrounding healthy tissue.
• Proton Therapy Advanced cancer treatment using proton beam radiation for precise tumor targeting with reduced exit dose to surrounding tissues.
• Theranostics Clinic (Yttrium-90 SIRT, Radium-223, Lutetium-177 PSMA, Lutetium-177 Octreotate) Specialized clinic delivering targeted nuclear medicine therapies including Yttrium-90 Selective Internal Radiation Therapy for liver cancer, Radium-223 (Xofigo) for castrate resistant prostate cancer with bone metastases, Lutetium-177 PSMA therapy for metastatic prostate cancer, and Lutetium-177 Octreotate therapy for neuroendocrine cancers.
• Systemic Cancer Therapy (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy) Systemic cancer treatments including chemotherapy (drugs that destroy cancer cells), immunotherapy (using the body's immune system against cancer), hormone therapy (reducing or blocking hormones to slow prostate cancer), and targeted therapy (drugs that target specific cancer cell mechanisms).
• Cryoablation and Radiofrequency Ablation Minimally invasive tumor ablation procedures using extreme cold (cryoablation) or electrical current heating (radiofrequency ablation) to freeze or destroy cancer cells.
• Prostate SBRT Clinic Specialized clinic dedicated to prostate cancer treatment using Stereotactic Body Radiation Therapy with MRI-guided planning, physician-directed image guidance, VMAT delivery, and SpaceOAR Hydrogel for rectal sparing.
• Liver Metastases SBRT Clinic Specialized clinic offering SBRT treatment for liver metastases and primary liver cancer using advanced stereotactic body radiation therapy techniques.
• Minimally-Invasive Oncology Minimally invasive oncology procedures complementing radiation therapy for cancer treatment, including ablation techniques and image-guided interventions.
• RECOVER@AARO (Radiation Side Effects Clinic) Specialized program providing prevention, monitoring, support, and therapeutic interventions for managing radiation therapy side effects and complications, including hyperbaric oxygen therapy for late effects such as osteoradionecrosis and radiation cystitis.

Quantifiable outcome

• 97% cancer control rate in low and intermediate risk prostate cancer patients at 5 years with SBRT treatment
• +3 more outcomes

Named customers4 records

Segments9 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Mount Miriam Hospital (MMCH)coreStrategic or Co-development Partner · 24 June 2026On June 24, 2026, AARO formalized a strategic alliance with Mount Miriam Hospital as Mission Partner to manage and operate the hospital's oncology services. Through the newly launched Mount Miriam Centre for Stereotactic Radiosurgery (MMCSR), AARO brings its Radiosurgery and Oncology management expertise from Singapore to Penang, Malaysia, extending world-class cancer care across Penang and northern Malaysia.
• ElektacoreTechnology or Integration · 1 May 2026Partnership with Elekta for Clinical Observership programs in Stereotactic & Advanced Radiotherapy. From May 11-15, 2026, conducted training workshop for radiation oncologists and medical physicists from Artemis Hospitals (Gurgaon) and AJ Hospital & Research Centre (Mangalore). The partnership enables knowledge transfer and features Elekta's treatment planning systems including Monaco 6.1.4.
• Singapore Cancer SocietycoreGTM or Marketing PartnerRegular collaboration on public education forums, cancer awareness talks, and community outreach programs. Dr. Teh spoke at Walnut Warriors prostate cancer support group. Dr. David Tan shared about colorectal cancer via Zoom with over 70 participants.
• 365 Cancer Prevention SocietyminorGTM or Marketing PartnerCollaboration on cancer prevention education. Dr. David Tan shared about lung cancer prevention and treatment at 365 CPS Love Lunch Talk via Zoom.
• International Atomic Energy Agency (IAEA)coreStrategic or Co-development PartnerDr. David Tan served as Singapore National Project Coordinator for IAEA Regional Project 6085 (2014-2020), enhancing SBRT for frequent cancers in Asia-Pacific. Established Singapore as a regional training hub and conducted first Regional Training Course in 2016 with participants from 17 member states.
• International Stereotactic Radiosurgery Society (ISRS)coreStrategic or Co-development PartnerDr. Daniel Tan serves on the Board of Directors of ISRS. AARO participates in ISRS Congresses and contributes to advancing global stereotactic radiosurgery practice.
• Artemis HospitalsminorStrategic or Co-development PartnerSenior radiation oncologists from Artemis Hospitals (Gurgaon, India) participated in AARO's Clinical Observership program in May 2026.
• AJ Hospital & Research CentreminorStrategic or Co-development PartnerMedical physicists from AJ Hospital & Research Centre (Mangalore, India) participated in AARO's Clinical Observership program in May 2026.
• Channel NewsAsia (CNA)minorGTM or Marketing PartnerMedia partnership for cancer education content. AARO doctors appeared on CNA Lifestyle features and CNA938 radio programs discussing cancer topics.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Singapore Medical Group (SMG) Oncology: SGX-listed private specialist healthcare group with oncology services among its multi-specialty portfolio in Singapore and the region. Comparable as an independent specialist oncology platform sharing the same private hospital ecosystem and patient demographic.
• Icon Cancer Centre (Singapore operations): Icon Group's Singapore subsidiary providing medical oncology, radiation oncology and haematology services at Mount Elizabeth, Gleneagles and other private hospitals. Direct overlap in SRS/SBRT, brachytherapy and theranostics with AARO at shared hospital sites.
• Parkway Cancer Centre: Private cancer centre within IHH Healthcare's Parkway network operating at Mount Elizabeth, Gleneagles and Parkway East hospitals in Singapore. Comparable as a multidisciplinary private oncology practice offering medical, radiation and surgical oncology at the same hospital partner sites as AARO.
• OncoCare Cancer Centre: Singapore-based private medical oncology practice offering specialist cancer consultations, chemotherapy and targeted therapy at multiple private hospital sites. Comparable as an independent Singapore specialist oncology group operating in the same private-hospital ecosystem as AARO.
• Icon Group: Australian-headquartered private cancer-care operator with day hospitals and radiation oncology centres across Singapore, Malaysia and broader Asia. Directly comparable as a specialist private oncology provider competing for the same regional private-pay and medical-tourist oncology volume.

Broad incumbents

• National Cancer Centre Singapore (NCCS): Singapore's largest public-sector specialty cancer centre, part of SingHealth. Comparable as the dominant specialty radiation oncology provider in the country and the source of AARO's founding clinicians; AARO effectively competes with NCCS on private convenience, technology and patient experience.
• IHH Healthcare (Mount Elizabeth, Gleneagles, Pantai): Asia's largest private hospital operator, owning Mount Elizabeth, Gleneagles and Pantai networks across Singapore and Malaysia. AARO delivers services inside several of its facilities; IHH is the counterparty landlord and an indirect competitor via in-house oncology tenants such as Parkway Cancer Centre.

Emerging players

• Lucence Health: Singapore-headquartered precision oncology company offering liquid biopsy and molecular diagnostics with emerging theranostics-adjacent capabilities. Comparable as a regional cancer-technology player addressing adjacent parts of the oncology value chain that AARO patients flow through.

Regional players

• Beacon Hospital: Private specialty hospital in Petaling Jaya, Malaysia with a dedicated cancer centre offering radiotherapy, chemotherapy and nuclear medicine. Comparable as a regional private radiation oncology competitor serving the Malaysian patient pool that AARO now also targets via Mount Miriam.
• Subang Jaya Medical Centre (SJMC): Ramsay Sime Darby private hospital in Malaysia offering comprehensive cancer care including radiotherapy. Comparable as a regional private hospital-based cancer service competing with AARO's Mount Miriam Centre for Stereotactic Radiosurgery in the northern Malaysia catchment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/272942286403512
• LinkedInlinkedin.com/company/asian-alliance-radiation-oncology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asian Alliance Radiation & Oncology